First-in-Human PET Imaging and Estimated Radiation Dosimetry of L-[5-11C]-Glutamine in Patients with Metastatic Colorectal Cancer

Allison S. Cohen; Joe Grudzinski; Gary T. Smith; Todd E. Peterson; Jennifer G. Whisenant; Tiffany L. Hickman; Kristen K. Ciombor; Dana Cardin; Cathy Eng; Laura W. Goff; Satya Das; J. Coffey Robert; Jordan D. Berlin; H. Charles Manning

doi:10.2967/jnumed.120.261594

First-in-Human PET Imaging and Estimated Radiation Dosimetry of L-[5-¹¹C]-Glutamine in Patients with Metastatic Colorectal Cancer

Allison S. Cohen, Joe Grudzinski, Gary T. Smith, Todd E. Peterson, Jennifer G. Whisenant, Tiffany L. Hickman, Kristen K. Ciombor, Dana Cardin, Cathy Eng, Laura W. Goff, Satya Das, J. Coffey Robert, Jordan D. Berlin, H. Charles Manning

Research output: Contribution to journal › Article › peer-review

13 Scopus citations

Abstract

Altered metabolism is a hallmark of cancer. In addition to glucose, glutamine is an important nutrient for cellular growth and proliferation. Noninvasive imaging via PET may help facilitate precision treatment of cancer through patient selection and monitoring of treatment response. L-[5-11C]-glutamine (11C-glutamine) is a PET tracer designed to study glutamine uptake and metabolism. The aim of this first-in-human study was to evaluate the radiologic safety and biodistribution of 11C-glutamine for oncologic PET imaging. Methods: Nine patients with confirmed metastatic colorectal cancer underwent PET/CT imaging. Patients received 337.97644.08 MBq of 11C-glutamine. Dynamic PET acquisitions that were centered over the abdomen or thorax were initiated simultaneously with intravenous tracer administration. After the dynamic acquisition, a whole-body PET/CT scan was acquired. Volume-of-interest analyses were performed to obtain estimatesoforgan- basedabsorbeddosesof radiation. Results: 11C-glutamine was well tolerated in all patients, with no observed safety concerns. The organs with the highest radiation exposure included the bladder, pancreas, and liver. The estimated effective dose was 4.46E-03±7.67E-04 mSv/MBq. Accumulation of 11C-glutamine was elevated and visualized in lung, brain, bone, and liver metastases, suggesting utility forcancer imaging. Conclusion: PET using 11C-glutamine appears safe for human use and allows noninvasive visualization of metastatic colon cancer lesions in multiple organs. Further studies are needed to elucidate its potential for other cancers and for monitoring response to treatment.

Original language	English (US)
Pages (from-to)	36-43
Number of pages	8
Journal	Journal of Nuclear Medicine
Volume	63
Issue number	1
DOIs	https://doi.org/10.2967/jnumed.120.261594
State	Published - Jan 1 2022
Externally published	Yes

Keywords

C-glutamine
PET
colorectal cancer
metabolism

ASJC Scopus subject areas

Radiology Nuclear Medicine and imaging

Access to Document

10.2967/jnumed.120.261594

Cite this

Cohen, A. S., Grudzinski, J., Smith, G. T., Peterson, T. E., Whisenant, J. G., Hickman, T. L., Ciombor, K. K., Cardin, D., Eng, C., Goff, L. W., Das, S., Robert, J. C., Berlin, J. D., & Manning, H. C. (2022). First-in-Human PET Imaging and Estimated Radiation Dosimetry of L-[5-¹¹C]-Glutamine in Patients with Metastatic Colorectal Cancer. Journal of Nuclear Medicine, 63(1), 36-43. https://doi.org/10.2967/jnumed.120.261594

Cohen, AS, Grudzinski, J, Smith, GT, Peterson, TE, Whisenant, JG, Hickman, TL, Ciombor, KK, Cardin, D, Eng, C, Goff, LW, Das, S, Robert, JC, Berlin, JD & Manning, HC 2022, 'First-in-Human PET Imaging and Estimated Radiation Dosimetry of L-[5-¹¹C]-Glutamine in Patients with Metastatic Colorectal Cancer', Journal of Nuclear Medicine, vol. 63, no. 1, pp. 36-43. https://doi.org/10.2967/jnumed.120.261594

@article{3ef5aa297dcf43a4b56c413818ed2fd7,

title = "First-in-Human PET Imaging and Estimated Radiation Dosimetry of L-[5-11C]-Glutamine in Patients with Metastatic Colorectal Cancer",

abstract = "Altered metabolism is a hallmark of cancer. In addition to glucose, glutamine is an important nutrient for cellular growth and proliferation. Noninvasive imaging via PET may help facilitate precision treatment of cancer through patient selection and monitoring of treatment response. L-[5-11C]-glutamine (11C-glutamine) is a PET tracer designed to study glutamine uptake and metabolism. The aim of this first-in-human study was to evaluate the radiologic safety and biodistribution of 11C-glutamine for oncologic PET imaging. Methods: Nine patients with confirmed metastatic colorectal cancer underwent PET/CT imaging. Patients received 337.97644.08 MBq of 11C-glutamine. Dynamic PET acquisitions that were centered over the abdomen or thorax were initiated simultaneously with intravenous tracer administration. After the dynamic acquisition, a whole-body PET/CT scan was acquired. Volume-of-interest analyses were performed to obtain estimatesoforgan- basedabsorbeddosesof radiation. Results: 11C-glutamine was well tolerated in all patients, with no observed safety concerns. The organs with the highest radiation exposure included the bladder, pancreas, and liver. The estimated effective dose was 4.46E-03±7.67E-04 mSv/MBq. Accumulation of 11C-glutamine was elevated and visualized in lung, brain, bone, and liver metastases, suggesting utility forcancer imaging. Conclusion: PET using 11C-glutamine appears safe for human use and allows noninvasive visualization of metastatic colon cancer lesions in multiple organs. Further studies are needed to elucidate its potential for other cancers and for monitoring response to treatment.",

keywords = "C-glutamine, PET, colorectal cancer, metabolism",

author = "Cohen, {Allison S.} and Joe Grudzinski and Smith, {Gary T.} and Peterson, {Todd E.} and Whisenant, {Jennifer G.} and Hickman, {Tiffany L.} and Ciombor, {Kristen K.} and Dana Cardin and Cathy Eng and Goff, {Laura W.} and Satya Das and Robert, {J. Coffey} and Berlin, {Jordan D.} and Manning, {H. Charles}",

note = "Funding Information: This work was supported by grants from the NIH (P30 CA068485, P50 CA236733, U24 CA220325, R35 CA197570, S10 OD019963, and S10 OD012297) and generous philanthropic funding from the Julia Reed Foundation, Debbie and Michael Rose Discovery Grant, and Samuel K. and Sandra G. Wellborn Cancer Discovery Grant. H. Charles Manning is a Cancer Prevention Research Institute of Texas (CPRIT) Scholar in Cancer Research and is supported by CPRIT RR200046. No other potential conflict of interest relevant to this article was reported. Publisher Copyright: {\textcopyright} 2022 by the Society of Nuclear Medicine and Molecular Imaging.",

year = "2022",

month = jan,

day = "1",

doi = "10.2967/jnumed.120.261594",

language = "English (US)",

volume = "63",

pages = "36--43",

journal = "Journal of Nuclear Medicine",

issn = "0161-5505",

publisher = "Society of Nuclear Medicine Inc.",

number = "1",

}

TY - JOUR

T1 - First-in-Human PET Imaging and Estimated Radiation Dosimetry of L-[5-11C]-Glutamine in Patients with Metastatic Colorectal Cancer

AU - Cohen, Allison S.

AU - Grudzinski, Joe

AU - Smith, Gary T.

AU - Peterson, Todd E.

AU - Whisenant, Jennifer G.

AU - Hickman, Tiffany L.

AU - Ciombor, Kristen K.

AU - Cardin, Dana

AU - Eng, Cathy

AU - Goff, Laura W.

AU - Das, Satya

AU - Robert, J. Coffey

AU - Berlin, Jordan D.

AU - Manning, H. Charles

N1 - Funding Information: This work was supported by grants from the NIH (P30 CA068485, P50 CA236733, U24 CA220325, R35 CA197570, S10 OD019963, and S10 OD012297) and generous philanthropic funding from the Julia Reed Foundation, Debbie and Michael Rose Discovery Grant, and Samuel K. and Sandra G. Wellborn Cancer Discovery Grant. H. Charles Manning is a Cancer Prevention Research Institute of Texas (CPRIT) Scholar in Cancer Research and is supported by CPRIT RR200046. No other potential conflict of interest relevant to this article was reported. Publisher Copyright: © 2022 by the Society of Nuclear Medicine and Molecular Imaging.

PY - 2022/1/1

Y1 - 2022/1/1

N2 - Altered metabolism is a hallmark of cancer. In addition to glucose, glutamine is an important nutrient for cellular growth and proliferation. Noninvasive imaging via PET may help facilitate precision treatment of cancer through patient selection and monitoring of treatment response. L-[5-11C]-glutamine (11C-glutamine) is a PET tracer designed to study glutamine uptake and metabolism. The aim of this first-in-human study was to evaluate the radiologic safety and biodistribution of 11C-glutamine for oncologic PET imaging. Methods: Nine patients with confirmed metastatic colorectal cancer underwent PET/CT imaging. Patients received 337.97644.08 MBq of 11C-glutamine. Dynamic PET acquisitions that were centered over the abdomen or thorax were initiated simultaneously with intravenous tracer administration. After the dynamic acquisition, a whole-body PET/CT scan was acquired. Volume-of-interest analyses were performed to obtain estimatesoforgan- basedabsorbeddosesof radiation. Results: 11C-glutamine was well tolerated in all patients, with no observed safety concerns. The organs with the highest radiation exposure included the bladder, pancreas, and liver. The estimated effective dose was 4.46E-03±7.67E-04 mSv/MBq. Accumulation of 11C-glutamine was elevated and visualized in lung, brain, bone, and liver metastases, suggesting utility forcancer imaging. Conclusion: PET using 11C-glutamine appears safe for human use and allows noninvasive visualization of metastatic colon cancer lesions in multiple organs. Further studies are needed to elucidate its potential for other cancers and for monitoring response to treatment.

AB - Altered metabolism is a hallmark of cancer. In addition to glucose, glutamine is an important nutrient for cellular growth and proliferation. Noninvasive imaging via PET may help facilitate precision treatment of cancer through patient selection and monitoring of treatment response. L-[5-11C]-glutamine (11C-glutamine) is a PET tracer designed to study glutamine uptake and metabolism. The aim of this first-in-human study was to evaluate the radiologic safety and biodistribution of 11C-glutamine for oncologic PET imaging. Methods: Nine patients with confirmed metastatic colorectal cancer underwent PET/CT imaging. Patients received 337.97644.08 MBq of 11C-glutamine. Dynamic PET acquisitions that were centered over the abdomen or thorax were initiated simultaneously with intravenous tracer administration. After the dynamic acquisition, a whole-body PET/CT scan was acquired. Volume-of-interest analyses were performed to obtain estimatesoforgan- basedabsorbeddosesof radiation. Results: 11C-glutamine was well tolerated in all patients, with no observed safety concerns. The organs with the highest radiation exposure included the bladder, pancreas, and liver. The estimated effective dose was 4.46E-03±7.67E-04 mSv/MBq. Accumulation of 11C-glutamine was elevated and visualized in lung, brain, bone, and liver metastases, suggesting utility forcancer imaging. Conclusion: PET using 11C-glutamine appears safe for human use and allows noninvasive visualization of metastatic colon cancer lesions in multiple organs. Further studies are needed to elucidate its potential for other cancers and for monitoring response to treatment.

KW - C-glutamine

KW - PET

KW - colorectal cancer

KW - metabolism

UR - http://www.scopus.com/inward/record.url?scp=85118594230&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85118594230&partnerID=8YFLogxK

U2 - 10.2967/jnumed.120.261594

DO - 10.2967/jnumed.120.261594

M3 - Article

C2 - 33931465

AN - SCOPUS:85118594230

SN - 0161-5505

VL - 63

SP - 36

EP - 43

JO - Journal of Nuclear Medicine

JF - Journal of Nuclear Medicine

IS - 1

ER -